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Cells adapt to nutrient and energy deprivation by
inducing autophagy, which is regulated by the
mammalian target of rapamycin (mTOR) and AMP-
activated protein kinases (AMPKs). We found that
cell metabolism significantly influences the ability
to induce autophagy, with mitochondrial complex I
function being an important factor in the initiation,
amplitude, and duration of the response. We show
that phenformin or genetic defects in complex I sup-
pressed autophagy induced by mTOR inhibitors,
whereas autophagy was enhanced by strategies
that increased mitochondrial metabolism. We report
that mTOR inhibitors significantly increased select
phospholipids and mitochondrial-associated mem-
branes (MAMs) in a complex I-dependent manner.
We attribute the complex I autophagy defect to
the inability to increaseMAMs, limiting phosphatidyl-
serine decarboxylase (PISD) activity and mitochon-
drial phosphatidylethanolamine (mtPE), which sup-
port autophagy. Our data reveal the dynamic and
metabolic regulation of autophagy.
INTRODUCTION
Autophagy targets long-lived proteins, complexmolecular struc-
tures, and organelles for lysosomal degradation, maintaining ho-
meostasis under basal conditions and generating molecular
building blocks to support essential cellular processes during
starvation. The term autophagy in the broadest sense includes
macroautophagy, microautophagy, and chaperone-mediated
autophagy (Yang and Klionsky, 2010). The multistep process
of macroautophagy, which we will call autophagy, responds to
signals that trigger (1) the formation of double-membrane auto-
phagosomes to sequester cargo, (2) trafficking along microtu-
bules, (3) fusion with the lytic compartment, and (4) enzymatic
degradation of contents to be released and recycled. Autophagy
is thus a catabolic process to supply metabolites for anabolic2404 Cell Reports 24, 2404–2417, August 28, 2018
This is an open access article under the CC BY-NC-ND license (http://processes. However, autophagy is anabolic in that it requires
the continued biosynthesis of autophagosomes, involving the
coordinate regulation of autophagy proteins, lipids, and suffi-
cient energy at localized regions of assembly (Kaur andDebnath,
2015; Yang and Klionsky, 2010). It is now recognized that auto-
phagy, initially thought to be nonselective in the sequestration of
cargo, is often selective, using adaptors or receptors to link spe-
cific cargo such asmitochondria to the growing autophagosome
(Farré and Subramani, 2016).
Autophagy is regulated by three interrelated protein kinases:
the mammalian target of rapamycin (mTOR), Unc-51-like kinase
1 (ULK1), and AMP-activated protein kinase (AMPK) (reviewed
by Russell et al., 2014). mTOR’s role in autophagy was estab-
lished more than 20 years ago and is conserved from yeast to
mammals. Specifically, TOR in yeast inhibits the activity of the
autophagy-related 1 kinase (Atg1), similar to mTOR’s inhibition
of ULK1, albeit with mechanistic differences (reviewed in
Noda, 2017). Autophagy is induced by starvation and rapamycin,
inhibitors of mTOR complex (mTORC) 1 (Yang and Klionsky,
2010), and by next-generation mTOR kinase inhibitors, which
are more potent inhibitors of mTORC1 and mTORC2 (Thomas
et al., 2012). However, it is possible to inhibit mTORC1 without
activating autophagy; for example, both mTORC1 and auto-
phagy are inhibited by lysosome inhibitors (Amaravadi et al.,
2011; Zoncu et al., 2011).
An understanding of AMPK’s role in autophagy was compli-
cated by early reports that the AMPK activator 5-aminoimida-
zole-4-carboxamide ribonucleotide (AICAR) inhibited autophagy
(Samari and Seglen, 1998), which was later found to be indepen-
dent of its effects on AMPK (Meley et al., 2006). Reports that
energy deprivation and subsequent activation of AMPKwere suf-
ficient, if not required, to inhibit mTOR (Gwinn et al., 2008; Inoki
et al., 2003; Kalender et al., 2010) suggested that AMPK induced
autophagy through inhibition ofmTOR.Amoredirect rolewases-
tablished when AMPK was shown to phosphorylate ULK1 (Egan
et al., 2011; Kim et al., 2011). The latter studies used multiple
tools, including AICAR, to activate AMPK and define ULK1 phos-
phorylation sites, althoughAICAR, asmentioned earlier, does not
induce autophagy (Samari and Seglen, 1998).
There are conflicting reports about the ability of other AMPK
activators to induce autophagy, e.g., glucose starvation orcreativecommons.org/licenses/by-nc-nd/4.0/).
phenformin (Ramirez-Peinado et al., 2013; Cheong et al., 2011).
These discrepancies may be caused by differences in cell types,
assay conditions, or methods to measure autophagy or may
reflect that the steps of autophagy require energy (Plomp
et al., 1989; Schellens and Meijer, 1991). Phenformin, described
as an inhibitor ofmitochondrial complex I (Owen et al., 2000), and
glucose starvation have different effects on energy metabolism
by targeting oxidative phosphorylation (OXPHOS) and glycol-
ysis, respectively. It has been argued that autophagy in response
to glucose starvation maintains energy homeostasis by supply-
ing substrates for the tricarboxylic acid (TCA) cycle (Cheong
et al., 2011), similar to reports that RAS oncogene-driven tumors
are addicted to autophagy to support metabolism and growth
(Guo et al., 2016; Yang et al., 2011). However, in cells treated
with phenformin, the role of autophagy in the switch to and sup-
port of aerobic glycolysis is not clear. The use of phenformin is
complicated by reports that it, like AICAR, does not induce auto-
phagy (Cheong et al., 2011). Others suggest that by targeting
OXPHOS, phenformin induces selective mitophagy (Shackelford
et al., 2013) to maintain energy equilibrium through amechanism
that involves phosphatase and tensin homolog (PTEN)-induced
putative kinase 1 (PINK1) and the E3 ubiquitin-protein ligase
PARKIN (Youle and Narendra, 2011). In yeast, however, defects
in mitochondrial respiration suppress rather than induce auto-
phagy (Graef and Nunnari, 2011). These inconsistencies raise
questions about the level of autophagy or mitophagy induced
by phenformin or the related biguanide, metformin, a commonly
used anti-diabetic drug. Phenformin and metformin are under
clinical investigation for pathologies in which autophagy’s role
is significant, including cancer and neurodegenerative disease
(Lorin et al., 2013; Menzies et al., 2017). Therefore, it is
critical to understand the degree to which agents that activate
AMPK affect autophagy to optimize treatments for the desired
outcome.
We initially set out to compare AMPK activators with mTOR in-
hibitors for their potency to induce autophagy and mitophagy.
We found that phenformin and glucose starvation had opposing
effects on autophagy and mitophagy, leading to a major shift in
our understanding of how energetic stress affects autophagy.
Autophagy was suppressed by phenformin and defects in com-
plex I but enhanced by glucose starvation and strategies to in-
creasemitochondrial metabolism. Furthermore, we demonstrate
that complex I activity was required for changes in phospholipid
metabolism and mitochondrial-associated membrane (MAM)
formation, which were increased by mTOR inhibition and impor-
tant for autophagy. Our findings demonstrate the importance of
metabolism in the regulation of autophagy, increase our under-
standing of the biological effects of clinically relevant biguanides,
and suggest strategies to activate or suppress this vital process.
RESULTS
Phenformin Inhibits Autophagy
As a positive control for autophagy, we combined the allosteric
and kinase mTOR inhibitors RAD001 and BEZ235 (RB), which
we had used previously in a preclinical model of hepatocellular
carcinoma (HCC) (Thomas et al., 2012). As an energetic
stressor, we initially chose phenformin, because it enters cellsmore readily than metformin and is reported to be 10 times
more potent (Shackelford et al., 2013). These studies were per-
formed primarily in HEK293 cells, which are capable of
mounting a robust autophagy response to starvation conditions
or mTOR inhibitors (Mercer et al., 2008, 2009; Thomas et al.,
2012) and are used routinely for studies associated with
mTOR and AMPK signaling (Auciello et al., 2014; Sancak
et al., 2010). Consistent with our previous work (Thomas
et al., 2012), RB strongly induced autophagy, as determined
by the betaine homocysteine S-methyltransferase (BHMT)
autophagy cargo assay and accumulation of a glutathione
S-transferase (GST)-BHMT fragment; by increased levels of
LC3-II, a marker of autophagy (Kabeya et al., 2000); and by
decreased levels of sequestome 1 (SQSTM1/p62), an adaptor
protein that selects ubiquitinated proteins for autophagy (Pan-
kiv et al., 2007) (Figures 1A and 1B). Unexpectedly, in phenfor-
min-treated cells, BHMT fragmentation and LC3-II levels did
not increase and SQSTM1/p62 levels were stable, despite acti-
vation of AMPK and inhibition of mTORC1 at later time points,
as determined by increased phosphorylation of acetyl-coA
carboxylase (ACC) and decreased phosphorylation of S6K1
and 4EBP1 (Figures 1A and 1B). We subsequently tested
increasing doses of phenformin for their ability to inhibit
mTOR and induce autophagy and found that phenformin did
not induce autophagy at any dose and suppressed the ampli-
tude of autophagy induced by RB in a dose-dependent manner
(Figure 1C). These results were supported by LC3-II flux ana-
lyses by western blotting (Figures 1D and 1E) and immunofluo-
rescence of LC3B puncta (Figures 1F and 1G). These findings
were not cell line or compound specific, because the bigua-
nides inhibited autophagy induced by mTOR inhibitors in multi-
ple cell lines, including liver kinase B1 (LKB1)-deficient A549
cells (Figures S1A–S1C), suggesting that AMPK activation is
not required for either the induction of autophagy by RB or its
inhibition by phenformin. Expression of proteins associated
with ULK1 or class III phosphatidylinositol (PtdIns) lipid kinase,
VPS34, which define complexes that initiate autophagy were
not changed by either treatment (Figure S1D). Finally, rotenone
and oligomycin, inhibitors of complex I and ATP synthase,
respectively, did not induce autophagy and inhibited RB-
induced autophagy at two time points (Figure S1E), suggesting
that respiration-competent mitochondria are essential for
autophagy. We conclude that phenformin does not induce
autophagy, despite mTOR inhibition and AMPK activation,
and inhibits autophagy induced by mTOR inhibitors.
Phenformin Inhibits Mitophagy
We reported that phenformin caused mitochondrial fragmenta-
tion and dysfunction in Huh7 cells (Veiga et al., 2018), conditions
that are conducive formitophagy (Pickles et al., 2018) and consis-
tent with reports that phenformin induces mitophagy (Egan et al.,
2011; Shackelford et al., 2013). Mitochondria in phenformin-
treated HEK293 cells also appeared fragmented and shifted
from dense to more buoyant fractions on a density gradient (Fig-
ures S2A and S2B). To measure mitophagy, we used the
GSTLSCSGFP-ActAmitophagy assay,which detects the autolyso-
somal degradation of a reporter protein embedded in the outer





































































































































































Figure 1. Phenformin Inhibits Autophagy
Induced by mTOR Inhibitors
(A and B) Time course of GST-BHMT autophagy
assay (A) and plotted ratio of the BHMT fragment/
GFP-myc (B) in HEK293 cells treated with vehicle
(V), 5 nM RAD001 and 20 nM BEZ235 (RB), or
1 mM phenformin (P1).
(C) GST-BHMT assay in HEK293 cells treated for
6 hr with 0–5 mM phenformin alone, or in combi-
nation with RB.
(D and E) LC3-II flux assay (D) and ratio of LC3-II/
ACTIN (E) in HEK293 cells treated as indicated.
(F and G) Representative confocal images (F) and
quantitation of LC3-B puncta/cell (G) in HEK293T
cells. Treatments as in (D) and (E). Scale bar is
10 mm. Data represented as mean ± 1 SD.Mitophagywas induced in cells treatedwithmTOR inhibitors (RB),
as determined by increased fragmentation of GSTLSCSGFP-ActA,
increased LC3-II (Figure 2A), and a significant reduction in mito-
chondrial mass (Figure 2B). These data are consistent with our
previous findings that RB induced mitophagy in mouse liver tu-
mors (Thomas et al., 2012) and the decreased mitochondrial
mass reported in cells treated with other mTOR kinase inhibitors
(Morita et al., 2013). To determine whether the decreased mito-
chondrial mass could be attributed to decreased mitochondrial
biogenesis, we measured expression of peroxisome prolifera-
tor-activated receptor gamma coactivator 1 alpha (PGC1a),
nuclear-respiratory factor 1 (NRF1), and transcription factor A,
mitochondrial (TFAM), which are reported to be regulated by
mTORC1 (Cunningham et al., 2007;Morita et al., 2013). However,
in the conditions used here, these transcriptional regulators were
not decreased by RB but instead were either unchanged or
increased (Figures S2C–S2E). Phenformin did not inducemitoph-
agy when used alone and inhibited RB-induced mitophagy (Fig-
ure 2A), similar to its inhibition of autophagy. To confirm these
data, we employed mitophagy reporter proteins fused to Keima
as described (An and Harper, 2018). Keima is an acid-stable fluo-
rescent protein that emits green or red signals at neutral or acidic
pH, respectively, and has been used to determine autophagy flux
(An and Harper, 2018; Katayama et al., 2011). In cells expressing
Mito-Keima, RB induced readily identifiable discreet red puncta2406 Cell Reports 24, 2404–2417, August 28, 2018suggestive of active mitophagy, whereas
there was little difference in the red
signal among vehicle (V), P, or RB plus
P (RBP) treatments (Figure 2C). The
mitochondrial import receptor subunit
TOMM20-Keima fusion protein on the
OMM is processed by lysosomal prote-
ases to produce an acid-stable form of
25 kDa. (An and Harper, 2018). Similar
to the GSTLSCSGFP-ActA assay (Fig-
ure 2A), the processed TOMM20-Keima
fragment was increased by RB, but not
phenformin (Figure S2F). In TOMM20-
Keima cells that overexpressed PARKIN,
Keima processing was blunted (Fig-
ure S2F), which may be because ofPARKIN’s E3 ubiquitin ligase activity and increased proteasome
degradation of OMM proteins (Yoshii et al., 2011). Further inves-
tigation showed that expression of PINK1, which is stabilized on
the OMM of damaged mitochondria (Narendra et al., 2010), did
not change in cells treated with RB, phenformin, metformin, or
rotenone, in contrast to its robust expression in cells treated
with oligomycin and antimycin A, inhibitors of mitochondrial
ATP synthase and complex III, respectively, or carbonyl cyanide
3-chlorophenyl hydrazone (CCCP), a mitochondrial uncoupler
(Figure S2G). The increased mitophagy observed with RB corre-
lated with decreased levels of TOM20 on the OMM (Figure S2G),
but notwith cytochrome c oxidaseassembly proteinCOX II on the
inner mitochondrial membrane (IMM) (Figure 2A). Furthermore,
mitochondrial complex I activity was increased in mitochondria
from RB-treated cells but was not significantly changed by phen-
formin (Figure 2D). The assay employed for these measurements
does not depend on ubiquinone, so complex I inhibitors that inter-
fere with the ubiquinone binding site, such as rotenone (Palmer
et al., 1968), do not inhibit activity. Phenformin may work through
a similar mechanism.We conclude that RB-inducedmitophagy is
distinct from a PINK1/PARKIN mechanism of mitophagy and is a
type of mitochondrial remodeling that preserves complex I activ-
ity. We found no evidence of mitophagy in phenformin-treated
cells, which may be partly because of the lack of PINK1 stabiliza-









































































































































































Figure 2. Phenformin Inhibits Mitophagy Induced by mTOR Inhibitors
(A) GSTLSCSGFP-ActA mitophagy assay in cells treated for 24 hr with V, RB, P
1, or RBP1.
(B) Mitochondrial DNA content, as measured by RT-qPCR. Statistics by one-way ANOVA.
(C) Representative confocal images from Mito-Keima expressing cells, treated for 4 hr.
(D) Complex I activity in mitochondria purified from HEK293 cells. 16 hr treatments.
**Adjusted p value = 0.0074. Data represented as mean ± 1 SD.suggesting that a common mechanism underlies phenformin’s
inhibition of both autophagy and mitophagy.
Phenformin’s Inhibition of Autophagy Is Not Explained
by Lysosome Defects
The inhibition of autophagy by phenformin could be attributed to
several mechanisms, including inhibition of mitochondrial com-
plex I, mitochondrial glycerophosphate dehydrogenase, one-
carbon metabolism, or the lysosome (Corominas-Faja et al.,
2012; Lockwood, 2010; Madiraju et al., 2014; Owen et al.,
2000). The latter was of particular interest, because lysosome
dysfunction inhibits both mTORC1 and autophagy (Amaravadi
et al., 2011; Zoncu et al., 2011) and metformin and phenformin
inhibit mTORC1 through a Rag-guanosine triphosphatase
(GTPase)-dependent mechanism at the lysosome (Kalender
et al., 2010). We reasoned that if phenformin inhibited mTORC1
by inhibiting lysosomal function, then mTORC1 would be insen-
sitive to amino acid starvation if it was tethered to the lysosome,
as shown in cells expressing FLAG-RAPTOR-RHEB15 (Sancak
et al., 2010). In control cells that expressed FLAG-RAPTOR,chloroquine (CQ), a lysosome inhibitor, and phenformin both in-
hibited mTORC1 activity in response to amino acid stimulation
(Figure S3A). However, in cells that express FLAG-RAPTOR-
RHEB15, mTORC1 activity was protected from amino acid
starvation in CQ-treated cells, as expected, but only partially
protected by phenformin. Furthermore, phenformin inhibited
mTORC1 in amino acid-starved FLAG-RAPTOR-RHEB15 cells
that were co-treated with CQ, suggesting that a significant part
of phenformin’s action is independent of the lysosome (Fig-
ure S3A). In support of this conclusion, LC3-II or LC3B puncta
did not accumulate in phenformin-treated cells (Figures 1A and
1D–1F) and lysosomal pH was unchanged by phenformin
(Figure S3B).
Defects inMitochondrial Complex I SuppressAutophagy
To determine whether phenformin’s inhibition of autophagy
was related to complex I inhibition, we measured autophagy
in cells with genetic deletion of complex I accessory subunits
whose importance in complex I assembly and activity was
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Figure 3. Autophagy Is Inhibited by Severe Defects in Mitochondrial
Complex I Accessory Subunits
(A) GST-BHMT assay in control andNDUFS6 orNDUFA10 knockout (KO) cells.
6 hr treatments. A numerical value for the BHMT fragment (frag)/GFP ratio,
normalized to RB, is shown.
(B) GST-BHMT assay in HEK293 cells treated for 6 hr, with or without 5 mM
nicotinamide (NM).
(C) GSTLSCSGFP-ActA mitophagy assay in HEK293T control and NDUFA1
KO
cells treated for 20 hr with V, RB, P1, RBP1, or 10 mM CCCP (CC).(KO) cell lines for these experiments: NDUFS6KO and
NDUFS4KO lines, which are viable in galactose media and rela-
tively competent in complex I assembly, and NDUFA1KO and
NDUFA10KO lines, which are not viable in galactose media
and have severe defects in complex I assembly (Stroud et al.,
2016). Basal mTORC1 activity appeared to be decreased in
the KO cells, whereas AMPK activity was increased only in
the cells with the more severe defect. In NDUFS6KO and
NDUFS4KO cells, RB-induced autophagy was nearly as robust
as autophagy in RB-treated control cells and was inhibited by2408 Cell Reports 24, 2404–2417, August 28, 2018phenformin to a similar degree (Figures 3A and S3C). In
contrast, the amplitude of RB-induced autophagy was reduced
in NDUFA10KO and NDUFA1KO cells and was not further
decreased by the addition of phenformin (Figures 3A and
S3C), suggesting that phenformin’s inhibition of autophagy is
primarily mediated by inhibition of complex I. BHMT fragmenta-
tion in vehicle-treated NDUF KO cells was less than in control
cells (Figures 3A and S3C), suggesting that basal autophagy
is suppressed by chronic defects in complex I.
Inhibition of complex I is reported to increase NADH and
NADH/NAD+ ratios (Birsoy et al., 2015; Sullivan et al., 2015),
and levels and metabolism of NAD+, the oxidized member of
this redox pair, have been linked to the regulation of auto-
phagy (reviewed in Jang et al., 2012). Therefore, we asked
whether phenformin’s inhibition of autophagy could be ex-
plained by changes in NADH/NAD+ ratios. We first determined
that phenformin treatment increased the NADH/NAD+ ratio in
HEK293 cells, which was largely reversed by the addition of
mTOR inhibitors (Figure S3D). Although supplementation
with nicotinamide (NM) to increase NAD+ biosynthesis
decreased NADH/NAD+ ratios (Figure S3D), NM did not
induce autophagy when used alone; it decreased RB-induced
autophagy and did not rescue phenformin’s inhibition of RB
autophagy (Figures 3B and S3E). The lack of correlation be-
tween NADH/NAD+ ratios and autophagy suggests that
increased NADH does not explain the autophagy defect asso-
ciated with phenformin.
Finally, as with autophagy, RB-induced mitophagy was
impaired in NDUFA1KO cells compared to control cells (Fig-
ure 3C), without further inhibition by phenformin. Although
CCCP did not induce measurable mitophagy in either cell line
(Figure 3C), we could occasionally detect modest mitophagy in
CCCP-treated HEK293 cells, but only at shorter time points (Fig-
ure S3F). PINK1 expression, although less robust in HEK293T
cells compared to HEK293 cells, was not increased in vehicle-
treated NDUFA1KO cells (Figure 3C), suggesting that complex I
defects do not activate PINK1-mediated mitophagy. Phenformin
and CCCP both induced cleavage of the IMM GTPase optic
atrophy 1 (OPA1), an energetic stress response that inhibits
membrane fusion activity (Toyama et al., 2016), consistent with
mitochondrial fragmentation (Figures S2A and S2B) (Veiga
et al., 2018) and supporting the efficacy of phenformin in these
cells. Altogether, these data show that defects in complex I
and mitochondrial respiration suppress autophagy in higher
eukaryotes, similar to what has been reported in yeast (Graef
and Nunnari, 2011).
Phenformin and Glucose Starvation Increase AMP/ATP
Energy Ratios and Cause Compensatory Metabolic
Switching
The suppression of autophagy andmitophagy by phenformin led
us to question whether there was sufficient energy in phenfor-
min-treated cells to support autophagy. Although it is widely
accepted that autophagy responds to energetic stress to in-
crease survival (Meijer and Codogno, 2011), autophagy con-
sumes ATP (Plomp et al., 1989), which suggests that cells
must maintain an energetic threshold to support autophagy.
















































6 hr 24 hr1 hr
V
hours1 4 8 24
1.5RBPRB
















































































Figure 4. Phenformin Suppresses the Initia-
tion, Amplitude, and Duration of Autophagy
(A) GST-BHMT assay in cells treated for 6 hr with
V, RB, P1, RBP1, with or without 1 mM adenosine.
(B) Bar graph of AMP/ATP ratios in HEK293 cells
treated with V, RB, P1, RBP1, or starved of
glucose.
(C and D) Immunofluorescence of WIPI2 in
HEK293T cells treated for 2 hr. Representative
confocal images (C) and quantification of WIPI2
puncta (D). Scale bar is 10 mm.
(E–G) GST-BHMT time course assay in cells
treated with V, RB, or RBP1.5, as shown by west-
ern blotting (E) and graphs of BHMT frag/GFP ra-
tios (F) and LC3-II/ACTIN ratios (G).increase ATP when used at millimolar concentrations (Li et al.,
2013), significantly increased ATP levels in HEK293 cells (Fig-
ure S4A), decreased phosphorylation of ACC, and enhanced
autophagy in response to mTOR inhibitors (Figure 4A) support-
ing the importance of ATP in fueling autophagy. To determine
the energetic status of cells in conditions that induced or in-
hibited autophagy, we measured AMP/ATP energy ratios at 1,
6, and 24 hr in cells treated with RB and/or phenformin. For com-
parison, we included glucose-starved cells as an alternative
means to induce energy stress. In RB-treated cells, the slight in-
crease in the AMP/ATP ratio at 1 hr adjusted to control levels
over time (Figure 4B). In contrast, AMP/ATP ratios in cells treated
with phenformin or starved of glucose for 1 hr increased more
than 25-fold (Figure 4B) with partial recovery over time, as cells
presumably adjusted to the energetic stress by switching from
OXPHOS to glycolysis, or vice versa. In support of such a switch,
phenformin significantly increased lactate at 2 time points in both
cells and media, decreased glucose levels, and depleted
glycogen stores (Figures S4B–S4F), consistent with glucose
consumption and a shift toward aerobic glycolysis. In contrast,
lactate levels in glucose-starved cells were significantly
decreased (Figure S4C), and the metabolites 3-hydroxyisobuty-
rate, 2-oxoisocaproate, and 3-methyl-2-oxovalerate were
increased in cells and/or media (Figures S4G and S4H), consis-
tent with the catabolism of branched chain amino acids BCAA toCell Repfuel the TCA cycle (Zhang et al., 2017).
The metabolic changes in RB-treated
cells more closely resembled glucose
starvation than phenformin treatment
(Figures S4B–S4E, S4G, and S4H). In
phenformin-treated cells, the nearly com-
plete recovery of AMP/ATP ratios at 6 hr
was not lasting but instead increased
again at 24 hr (Figure 4B), a rise that par-
alleled increasing phosphorylation of
ACC (Figures 1A and 4E).
Phenformin Suppresses the
Initiation, Amplitude, and Duration
of Autophagy
We predicted that if phenformin’s inhibi-
tion of RB-induced autophagy was dueto energy depletion, it was likely to occur at early time points
when energy ratios were most severely affected. The WD-40
repeat domain phosphoinositide-interacting protein 2 (WIPI2)
is a mammalian Atg18 ortholog that is recruited to early auto-
phagosome structures, where it binds PtdIns3P, a product of
VPS34/ATG14/BECLIN1 complex activity, and supports LC3
lipidation (Polson et al., 2010). We observed a decrease in
WIPI2 puncta and the rate of LC3-II accumulation in RBP-
treated cells, compared to RB treatment (Figures 4C, 4D,
and S4H–S4K), suggesting that phenformin decreased early
autophagosome formation. Despite this, there was little differ-
ence in the GST-BHMT fragment between cells treated with
RB or RBP at 2 hr (Figures 4E and 4F) or in SQSTM1/p62
levels (Figure 1D), suggesting that the decreased rate of auto-
phagosome formation had little effect on the initial sequestra-
tion, delivery, or degradation of autophagy cargo. At subse-
quent time points, however, the amplitude of autophagy in
RBP cells fell below that of RB-treated cells. Furthermore, in
contrast to the stability of the GST-BHMT fragment in RB-
treated cells (Figures 1A and 4E), the reporter fragment in
RBP-treated cells declined after 8 hr (Figures 4E and 4F).
The fragment decay is consistent with attenuated autophagy
and decreased cargo delivery; we could induce a similar
decrease in BHMT fragment levels by treating cells 5 hr after
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Figure 5. Glucose Starvation Increases
Autophagy and Mitophagy
(A and B) GST-BHMT assay time course in cells
treated with V or RB, in media with 25 or 0 mM
glucose, as shown by western blotting (A) and
graph of BHMT frag/GFP ratio (B).
(C) GST-BHMT assay in cells treated for 24 hr with
vehicle or RB in DMEM with 25 or 0 mM glucose,
25 mM galactose (Gal), or 100 mM trehalose
(Treh).
(D) GSTLSCSGFP-ActA mitophagy assay in cells
treated for 24 hr with 25, 5, or 0 mM glucose;
25 mM Gal; or P1, without or with RB.trafficking or autophagosome and lysosome fusion (Figures
S4M and S4N). We conclude that (1) although ATP clearly sup-
ports autophagy, severe defects in energetic ratios do not pre-
vent the initial sequestration of autophagic cargo induced by
mTOR inhibitors, and (2) phenformin suppresses autophagy
progression through a defect in autophagosome biogenesis.
Prolonged Glucose Starvation Increases Autophagy and
Mitophagy
Although the effects of glucose starvation and phenformin on
AMP/ATP ratios were similar, their effects on autophagy were
different. In glucose-starved cells, GST-BHMT fragmentation
and LC3-II levels, although initially unchanged, were
increased at 24 hr (Figure 5A), consistent with reports that
glucose starvation induces autophagy (Cheong et al., 2011;
Kim et al., 2011). However, there was little correlation be-
tween the kinetics of AMPK activation, which occurred early,
and the late induction of autophagy. In RB-treated cells, auto-
phagy in glucose-depleted medium at early time points was
comparable to autophagy in high-glucose DMEM but ex-
ceeded that of RB in high glucose at 24 hr and was stable
up to 36 hr (Figures 5A, 5B, and S5A). Consistent with these
findings, replacing glucose with either galactose, which pro-
vides no net ATP from aerobic glycolysis (Marroquin et al.,
2007), or trehalose, a non-fermentable sugar that inhibits
glucose transport (DeBosch et al., 2016), also increased auto-
phagy and enhanced RB-induced autophagy (Figure 5C). It is
likely that glucose-starved cells use TCA substrates like gluta-
mine to support OXPHOS and survival (Wise and Thompson,
2010). Consistent with the importance of mitochondrial
function for autophagy, supplementation of glucose-replete
DMEM with the anapleurotic amino acids glutamine or aspar-
tate increased the amplitude of RB-induced autophagy,
although neither amino acid rescued the autophagy defect
in cells treated with RBP (Figures S5B and S5C), consistent
with a phenformin defect in complex I and OXPHOS. Finally,2410 Cell Reports 24, 2404–2417, August 28, 2018mitophagy in response to glucose star-
vation or galactose treatment was
nearly as robust as mitophagy in RB-
treated cells (Figure 5D) but was not
observed in cells starved of essential
amino acids (Figure S5D). We conclude
that metabolic conditions that favor
mitochondrial function and respirationalso increase the amplitude of autophagy and mitophagy, in-
dependent of unfavorable AMP/ATP energy ratios.
Phospholipid Remodeling in Autophagy
The lack of correlation between energetic ratios and autophagy
led us to consider phenformin’s effects on phosphatidyletha-
nolamine (PE) biosynthesis. Levels of lipidated LC3-II were
often decreased in cells treated for 24 hr with phenformin (Fig-
ures 4E, 4G, 5D, and S5D), suggesting that phenformin may
limit either the synthesis or the availability of PE, a phospholipid
that is covalently attached to membrane-bound LC3 (Kabeya
et al., 2004) and required for autophagy (Rockenfeller et al.,
2015). Using targeted lipidomics, we found that phenformin
alone had little effect on phospholipids, whereas RB signifi-
cantly increased select species of PE and phosphatidylserine
(PS) (Figures 6A, S6A, and S6B). PE (18:0/18:1) levels did not
increase in cells treated with RBP, consistent with phenformin’s
inhibition of RB-induced autophagy. In mammalian cells,
distinct pools of PE are synthesized on either mitochondria or
endoplasmic reticulum (ER) membranes (Vance and Tasseva,
2013), and the mitochondrial phosphatidylethanolamine
(mtPE) pool is reported to support autophagosome formation
in starved cells (Hailey et al., 2010). To determine the impor-
tance of mtPE for RB autophagy, we measured autophagy in
cells with 2 small interfering RNAs (siRNAs) targeting PISD,
an IMM enzyme that converts PS to mtPE. Cells with
silencing phosphatidylserine decarboxylase (siPISD) were
visibly stressed, with cleaved poly(ADP-ribose) polymerase 1
(PARP), indicative of early apoptosis, in siPISD-6 cells with
the more severe knockdown (Figures 6B and S6C). These
data are consistent with reports that loss of PISD causes
defects in mitochondrial morphology and function, disrupts
electron transport chain (ETC) complex formation, and is em-
bryonic lethal in mice (reviewed in Vance and Tasseva, 2013).
Basal autophagy was increased only in siPISD-6 cells, sug-
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Figure 6. Phospholipid Remodeling in
Autophagy
(A) Levels of PE (18:0/18:1) and PS (18:0/18:1) in
HEK293 cells treated for 24 hr with V, RB, P1, or
RBP1. ****p < 0.0001, ***p = 0.0002. ns = not sig-
nificant. Data represented as mean ± 1 SD.
(B) GST-BHMT autophagy assay in cells trans-
fected with non-silencing siRNA (siNS), siPISD-6,
or siPISD-7. Cells were treated for 6 hr.
(C) GST-BHMT autophagy assay in cells treated
for 6 hr with drugs as indicated, with 5mML-serine
and/or 1 mM hydroxylamine as noted.
(D) GST-BHMT autophagy assay in cells treated
for 6 hr as indicated, with buffer or mixed
composition liposomes.of autophagy associated with apoptosis, a phenomenon also
observed with the chemotherapy drug doxorubicin (Figure S6D).
Despite this, the magnitude of RB-induced autophagy was
decreased by knockdown of siPISD when compared to non-
silencing siRNA (siNS) control cells, and was further reduced
by the addition of phenformin (Figure 6B). The latter suggests
that complex I assembly was not fully compromised by partial
PISD knockdown. To inhibit PISD more acutely, we used the
PISD inhibitor hydroxylamine (Shiao et al., 1995; Voelker,
1993), which inhibited RB-induced autophagy without signs of
apoptosis when used at 0.1 or 1 mM doses (Figure S6D).
Others have shown that PISD activity is increased by exoge-
nous serine (Shiao et al., 1995; Voelker, 1993), a non-essential
amino acid that supports PS, sphingosine, and purine biosyn-
thesis (Locasale, 2013). Adding serine to DMEM increased
the amplitude of RB autophagy, which was reversed by the
PISD inhibitor hydroxylamine (Figure 6C), supporting the impor-
tance of PISD activity and mtPE for autophagy. The addition of
ethanolamine (ETN) to medium to favor ER biosynthesis of PE
through the Kennedy pathway (Calzada et al., 2016) or mixed
phospholipid liposomes also increased the amplitude of RBCell Repautophagy, although neither rescued
the autophagy defect associated with
phenformin (Figures 6D and S6F). We
conclude that mTOR inhibitors enhance
both phospholipid remodeling and auto-
phagy that depends on PISD activity and
mtPE, as well as that phenformin blocks
the biosynthesis of mtPE.
Phenformin Blocks MAMs that
Support Autophagy
We reasoned that phenformin might
affect mtPE biosynthesis under auto-
phagy-inducing conditions by limiting
the availability of PS, the substrate for
PISD (Di Bartolomeo et al., 2017). PS
translocates from the ER to mitochon-
dria at MAMs, which are regions of
proximity between the ER and the
mitochondria that support mitochondrial
function (Naon and Scorrano, 2014) andautophagy, the latter through recruitment of ATG14 and VPS34
(Hamasaki et al., 2013). To determine the effect of our treat-
ments on MAM formation, we used a proximity ligation assay
with antibodies to inositol trisphosphate receptor (IP3R) and
voltage-dependent anion channel (VDAC) on the ER and the
OMM, respectively. We found that RB significantly increased
the number of MAM contact sites compared to vehicle control
(Figures 7A and 7B), consistent with the increase of WIPI2
puncta (Figures 4C and 4D), and autophagosome formation
at MAMs (Hamasaki et al., 2013). Phenformin alone had little
effect on MAM formation, but when combined with RB, it
reduced the number of MAM contact sites compared to RB
alone (Figures 7A and 7B). Moreover, MAMs did not increase
in NDUFA1KO cells treated with RB (Figures 7A and 7B), sup-
porting the importance of complex I activity for autophagy.
Finally, prolonged glucose starvation, which induced both a
metabolic shift toward OXPHOS and autophagy (Figures 5,
S5, and S4), increased MAM formation to levels equivalent to
RB treatment (Figure S7), consistent with reports that MAM for-
mation is sensitive to glucose availability (Theurey et al., 2016).
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Figure 7. Defects in Complex I Prevent the
Significant Increase in MAMs that Occurs
with mTOR Inhibitors
(A) Proximity ligation assay showing MAMs by
confocal microscopy. HEK293T cells were treated
for 4 hr. Scale bar is 10 mm.
(B) Scatter plot graph showing quantified MAMs
data. ****p < 0.0001. ns = not significant. Data
represented as mean ± 1 SD.
(C) Model of conditions that support or
inhibit autophagy. Left: mTOR inhibitors (RB)
induce active autophagy in cells with healthy
mitochondria by increasing MAMs, sites of ATG14
recruitment and phospholipid transport, support-
ing mtPE biosynthesis and sustained autophagy.
RB autophagy is enhanced by conditions that in-
crease TCA intermediates, ATP, or phospholipids.
Right: Autophagy is impaired by phenformin or
defects in complex I, which prevent the increase of
MAMs induced by mTOR inhibitors, local ATP,
and the ATP-dependent transfer of PS for mtPE
biosynthesis.activity is required to facilitate the transport of PS from the ER
to mitochondria at MAMs, supplying PS substrate for the
biosynthesis of mtPE and supporting both respiratory function
and autophagy (Figure 7C).
DISCUSSION
Mitochondrial Metabolism Supports Autophagy
Understanding the relationship between autophagy and meta-
bolism has previously focused on how autophagy fuels meta-
bolism, supporting cell survival (Kimmelman and White, 2017).
Our data demonstrate that a reciprocal relationship is also2412 Cell Reports 24, 2404–2417, August 28, 2018true, with metabolism regulating the
amplitude of the autophagy response.
We showed that a metabolic shift to-
ward aerobic glycolysis decreased auto-
phagy, whereas a shift toward OXPHOS
increased the amplitude of autophagy,
most strikingly in response to mTOR
inhibitors. In the setting of cancer, the
high metabolic demand of tumor cells,
particularly those with activated RAS
signaling, often depends on autophagy
(Kimmelman and White, 2017), leading
to clinical trials using lysosomal inhibi-
tors to target autophagy directly and
metabolism indirectly. Our data suggest
that targeting mitochondrial OXPHOS
for cancer therapy (Weinberg and Chan-
del, 2015) will inhibit both mitochondrial
metabolism and autophagy,
Clinically, there is considerable inter-
est in using metformin and phenformin
for cancer treatment (Weinberg andChan-
del, 2015), with nearly 100 actively recruit-
ing clinical trials (https://clinicaltrials.gov/).Our data show that biguanides inhibit mTORC1 without the
complication of activating autophagy and cause a metabolic shift
toward glycolysis.We reported that the sequential use of phenfor-
min and RB significantly prolonged survival in a mouse model of
HCC, suggesting that phenformin metabolically sensitized HCC
tumors to mTOR inhibitors (Veiga et al., 2018). It remains to
be determined whether phenformin pretreatment blocked RB-
induced autophagy in vivo, contributing to the efficacy of the com-
bination. For tumors that are addicted to autophagy, the potential
use of biguanides as autophagy inhibitors provides an alternative
to CQ or hydroxychloroquine, without the disadvantages associ-
ated with profound lysosomal inhibition.
Complex I Defects Suppress Autophagy
We found lower basal autophagy in NDUF KO cells and an in-
verse correlation between the severity of the complex I defect
and the amplitude of RB-induced autophagy. Mutations in
each of the complex I assembly subunits used here have been
implicated in Leigh syndrome, a pediatric mitochondrial disease
marked by progressive neurodegeneration and early death (Ro-
denburg, 2016). Suppression of basal autophagy in mice with
neuronal deletion of ATG5 was a contributing factor to their neu-
rodegeneration (Hara et al., 2006), suggesting that defects in
autophagy may contribute to the pathology of Leigh syndrome
and other mitochondrial diseases. Rapamycin has been shown
to slow disease progression in an Ndufs4/ mouse model of
Leigh syndrome (Johnson et al., 2013) and in induced pluripotent
stem cells (iPSCs) derived from a Leigh syndrome patient (Zheng
et al., 2016). In the NDUF KO cells used here, RB treatment
induced varying degrees of autophagy above basal levels, albeit
lower than that of wild-type (WT) cells. It will be important to
determine whether more potent mTOR kinase inhibitors will pro-
vide an improved benefit in models of mitochondrial disease and
whether autophagy and mitophagy are contributing factors.
AMP/ATP Energy Ratios, AMPK, and Autophagy
These data redefine how energetic stress affects autophagy, a
dynamic program that requires energy for its execution (Meijer
and Codogno, 2011; Plomp et al., 1989). A paradox of these
studies is that RB-induced autophagy was amplified by both en-
ergy excess (adenosine) and energy deprivation (glucose starva-
tion). Strategies to decrease ATP and activate AMPK did not
acutely activate autophagy, although autophagy was measur-
ably increased by prolonged glucose starvation. These data
are consistent with those of Cheong et al. (2011), who argued
that autophagy in response to glucose starvation is not due to
bioenergetics failure but is instead caused by the accumulation
of ammonia, an explanation that is consistent with much of our
data. However, the finding that autophagy was increased
when galactose was used as a carbon source argues for
another mechanism, because galactose metabolism consumes
ammonia but does not increase it (Roser et al., 2009). One expla-
nation to resolve the energy and autophagy paradox is that cells
that switch to, or enhance, mitochondrial OXPHOS increase ATP
in a temporal and spatial manner at MAMs, where the ATP-
dependent processes of PS transport and autophagosome for-
mation are active (Hamasaki et al., 2013; Shiao et al., 1995).
This idea is supported by the presence of the ATP transporter
VDAC at MAMs (Naon and Scorrano, 2014).
There was little correlation between acute AMPK activation
and the late onset of autophagy in glucose-starved cells. Our
data suggest that in cells with intact complex I function, mTOR
inhibition is dominant in the acute activation of autophagy,
whereas AMPK supports a secondwave in a biphasic autophagy
mechanism. The delayed effect could be explained by transcrip-
tional changes (Pietrocola et al., 2013; Shin et al., 2016) or
through the effects of increased b-oxidation, as suggested (Buz-
zai et al., 2005; Cheong et al., 2011). However, these effects do
not explain the relevance of AMPK’s acute phosphorylation of
ULK1 that has been linked to autophagy (Egan et al., 2011;
Kim et al., 2011). We propose that because ULK1 and ULK2are dispensable for glucose starvation autophagy (Cheong
et al., 2011), AMPK phosphorylation of ULK1/2 may be linked
to either selective autophagy and/or metabolism. Consistent
with this idea, Snf1 and Atg1, the yeast orthologs of AMPK and
ULK1, control glycogen-specific autophagy (Wang et al.,
2001), and the ULKs regulate glucose metabolic flux in starved
cells independent of autophagy (Li et al., 2016). Additional
studies are needed to more fully delineate the AMPK-ULK axis
in glucose metabolism.
mTOR Inhibitors Increase Mitophagy
mTOR inhibitors and glucose starvation induced measurable
and sustained mitophagy while preserving complex I activity,
consistent with a report that mitophagy is induced by conditions
that favor mitochondrial OXPHOS to optimize mitochondrial effi-
ciency (Melser et al., 2013). In contrast, phenformin did not
induce mitophagy, and the response to CCCP was nearly unde-
tectable. Furthermore, mitophagy following prolonged CCCP
treatment was lower than in vehicle-treated cells and compara-
ble to levels found in NDUFA1 KO cells, consistent with the idea
that mitochondrial function and mitophagy are mutually depen-
dent. RB-induced mitophagy was independent of PINK1, which
cooperates with PARKIN to remove damagedmitochondria. Mu-
tations in PINK1 and PARKIN are associated with Parkinson’s
disease (PD), implicating defective mitophagy in disease patho-
genesis (Pickrell and Youle, 2015). Our data suggest that the
potent mitophagy induced by mTOR inhibitors could serve as
a mitochondrial quality mechanism independent of PINK1/
PARKIN mitophagy for PD patients. Consistent with this idea,
rapamycins have shown promise in models of PD and other
neurodegenerative diseases (Bové et al., 2011). More potent
mTOR kinase inhibitors may provide additional benefit for PD
treatment, and their efficacy might be improved by metabolic
strategies to amplify autophagy. Of these, trehalose and ETN
have shown promise as agents to protect against aggregates
associated with neurodegenerative disease or promote
longevity (Rockenfeller et al., 2015; Sarkar et al., 2007). We hy-
pothesize that complete inhibition of mTORC1 triggers selective
mitophagy, just as it selectively regulates energetically costly
biosynthetic pathways through post-translational modifications.
This is consistent with the idea that mTORC1 coordinates both
mitochondrial mass and protein synthesis to balance energetic
output with demand (Morita et al., 2013).
MAMs and mtPE Play a Significant Role in Autophagy
PE is a positive regulator of autophagy (Rockenfeller et al., 2015);
however, autophagy competes with other PE-consuming pro-
cesses for the available phospholipid pool (Wilson-Zbinden
et al., 2015), suggesting that PE is limiting for autophagy.
mTOR inhibitors increased the abundance of select phospho-
lipids, in correlation with increased autophagy. The increase in
C18:0 and C18:1 phospholipid acyl chains are consistent with
those identified in PE-lipidated Atg8 (Ichimura et al., 2000). We
conclude, based on several pieces of evidence, that mtPE is
the relevant species for autophagy. First, RB autophagy was
suppressed by inhibiting PISD and increased with exogenous
serine, which is purported to increase PISD activity (Shiao
et al., 1995; Voelker, 1993). Serine and hydroxylamine mayCell Reports 24, 2404–2417, August 28, 2018 2413
have other effects that are relevant for autophagy apart from
PISD activity, requiring future work to validate their specific ef-
fects on mtPE biosynthesis in this context. Second, data
showing that phenformin blocked the ability of ETN and phos-
pholiposomes to increase RB-induced autophagy, and the RB-
associated increase in MAMs, supports the importance of PS
transport and substrate availability for PISD activity. This is
related to PS transport being regulated by mitochondria respira-
tion in yeast and mammalian cells (Miyata et al., 2016; Shiao
et al., 1995).We propose that the increased autophagy observed
with adenosine, glutamine, and aspartate is partly due to
increased respiration, phospholipid transport, and mtPE biosyn-
thesis. The possibility that PISD supports autophagy simply by
promoting ETC activity cannot be ruled out. However, the in-
crease in PE and autophagy, but not ATP, in cells treated with
mTOR inhibitors, and the initiation of autophagy in energetically
stressed cells, favors the importance of PISD-derived mtPE for
autophagy. Future studies are needed to determine the physio-
logical relevance of strategies that combine mTOR inhibition
with manipulation of mtPE biosynthesis in pathologies in which
autophagy is relevant. We are drawn to several hypotheses
regarding how phenformin inhibits mtPE biosynthesis, each of
which requires further investigation. First, mitochondrial frag-
mentation and the imbalance of fission to fusion may not be
conducive to inter-organelle contact. The converse is true,
because positive signals for autophagy, e.g., starvation or
mTOR inhibitors, promote fusion, OXPHOS (Gomes et al.,
2011; Veiga et al., 2018), and MAMs (data in this paper; Bravo-
Sagua et al., 2016; Theurey et al., 2016). Second, decreased
respiration may change the expression of proteins required for
PS transport, as shown in yeast (Miyata et al., 2016), or decrease
the local availability of ATP for PS transport and MAM formation.
Finally, we cannot rule out that post-translation modifications
control MAM formation in a more acute manner. Altogether,
these data demonstrate the dynamic and metabolic regulation
of autophagy, highlighting the importance of mitochondrial com-
plex I and respiration for a robust autophagy response.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture and experimental conditions
All cells were cultured at 37C, in 5% CO2, in DMEM containing essential and non-essential amino acids, 4 mM glutamine, 1 mM
sodium pyruvate, and 10% fetal calf serum (FCS). Experiments with glucose or amino acid starvation, galactose, or trehalose
contained FCS dialyzed extensively against 25 mM HEPES pH 7.3, 50 mM NaCl, using Spectra/Por membrane with MWCO 3500
(Spectrum Labs).
Cell lines used in this study
d HEK293 cells (human, sex unknown, embryonic kidney, ATCC CRL-1573, RRID:CVCL_0045)
d HEK293 Keima knock-in cells were generously provided by J. Wade Harper (An and Harper, 2018).
d HEK293T cells (human, sex unknown, embryonic kidney, RRID:CVCL_0063)
d HEK293T cells with genetic deletion of NDUFA1, NDUFA10, NDUFS4 and NDUFS6 were cultured in DMEM supplemented
50 mg/ml uridine. Uridine was added to DMEM for both HEK293T parental and KO cells under experimental conditions. These
cells were generously provided by Michael T. Ryan (Stroud et al., 2016).
d For experiments in HEK293T cells that stably express Flag-RAPTOR and Flag-RAPTOR-RHEB15, cell media was refreshed
with a half media change 6 h before treatment. At time zero, cells were placed in DMEM with 25 mM glucose, 1 mM pyruvate
and 4 mM glutamine, but without essential amino acids or serum for 60 minutes. For amino acid stimulation, a mix of essential
amino acids (EAA) was added during the last 10 minutes, for final EAA concentrations equal to 1x DMEM.
d A549 cells (human, male, lung epithelial carcinoma, ATCC CCL-185, RRID:CVCL_0023)
d Hep3b cells (human, male, hepatocellular carcinoma, ATCC HB-8064, RRID:CVCL_0326)
d H9C2 (2-1) cells (rat, embryonic myoblast, ATCC CRL-1446, RRID:CVCL_286)
GST-BHMT and GSTLSCSGFP autophagy assays
The GST-BHMT and GSTLSCSGFP assays were performed as previously described (Dennis andMercer, 2009; Mercer et al., 2008). In
brief, cells expressing GST-BHMT-IRES-GFPmyc, GSTLSCSGFP, or GSTLSCSGFP-ActA were cultured for the times indicated, with
drugs or treatments as described. 5 nM RAD001 and 20 nM BEZ235 served as a positive control to induce autophagy/mitophagy.
Leupeptin (11 mM) and E64d (6 mM) were added at the beginning of each treatment. The following steps were performed on ice or at
4C. Except for Figure S4B, which were harvested for light membrane fractions (LMFs) or unless otherwise indicated in the Fig-
ure panel, cells were harvested in extraction buffer (EB) with 1% Triton X-100 (EB-TX) (50 mM TRIS-HCl pH 8, 120 mM NaCl,
5 mM NaPPI, 10 mM NaF, 30 mM para-nitrophenylphosphate, 1 mM benzamidine, 0.2% NP-40 and fresh 0.2 mM PMSF). Total pro-
tein was determined by the Bradford method; and GST-BHMT was precipitated with glutathione agarose from 300-400 mg of cell
lysate. Bound GST-proteins were washed once in EB with 500 mM NaCl, and 1-2 times in wash buffer (50 mM MOPS pH 7.5,
10 mMNaF, 30 mM b-gycerolphosphate, 1 mMDTT, 0.1% Triton X-100, 10% glycerol). Precipitates were boiled in SDS-PAGE sam-
ple buffer, eluted, resolved by SDS-PAGE, followed by western blotting and imaging with the Odyssey system. Whole cell lysates
(25-30 mg) were resolved by SDS-PAGE, followed by western blotting and imaging with the Odyssey system, and probed for anti-
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(IRES), was used to normalize expression of the GST-BHMT-IRES-GFPmyc plasmid. The GST-BHMT fragment and GFP myc den-
sities were quantified using the LiCOR imaging software, and the GST-BHMT frag/GFP ratio was calculated as an autophagy index.
Raw ratios are shown on all graphs, whereas the numerical autophagy ‘‘index’’ is shown on western blots, with normalization to the
RB GST-BHMT frag/GFP ratio represented as 1.0.
GSTLSCSGFP-ActA mitophagy assay
The GSTLSCSGFP-ActA mitophagy assay was performed as previously described (Dennis and Mercer, 2009) from LMFs. All steps
were performed on ice or at 4C. PBS-washed cells were collected and centrifuged at 1000xg for 5min; the cell pellet was suspended
in 400-500 ml homogenization buffer (HB) (10 mM TRIS pH 7.5, 300 mM sucrose, 0.2 mM EDTA, 0.2 mM PMSF) and disrupted by
Dounce homogenization for 10-15 strokes. The homogenate was centrifuged at 540 xg and the supernatant was collected. The ho-
mogenization step was repeated with the low speed pellet, and the combined supernatant was centrifuged at 12,000 xg for 20 min to
separate the LMF in the pellet from the high-speed supernatant (HSS). The LMF fraction was homogenized in EB-TX, LMF protein
was determined by Bradford method, and GST-tagged proteins were precipitated with glutathione agarose from 50 or more ug of
LMF extract. Bound GST proteins were washed, boiled in SDS-sample buffer, eluted, resolved by SDS-PAGE and visualized as
described above. 10 mg of LMF extract was resolved by SDS-PAGE, followed by western blotting for mitochondria and autolysoso-
mal proteins as described.
LC3-II flux autophagy assay
Cells were pre-treated for 1h with drugs as described, then treated with 100 mM chloroquine (CQ), and harvested after 40 minutes.
The time of harvest was based on preliminary time course studies to determine the optimal time to capture differences between con-
trol and autophagy inducing conditions. Cells were harvested in EB-TX, total protein was determined by Bradford assay, and 25 mg of
total extract was resolved by SDS-PAGE, followed by western blotting for LC3, and other proteins as described. For LC3-II rate anal-
ysis, cells were treated as described above with drugs and CQ, and cells were harvested at time points as described. In both assays,
levels of LC3-II were normalized to ACTIN.
LC3B and WIPI2 immunofluorescence
HEK293 cells were seeded on 35 mm coverslip collagen coated dishes (MatTek), grown to 65%–70% confluency. For LC3B
puncta, cells were treated as described for the LC3-II flux assay. For WIPI2 puncta, cells were treated for 2 h. Cells were washed
with PBS, fixed with ice cold methanol, rinsed x3 with PBS, permeabilized with 0.1% saponin in PBS, blocked with 1% BSA,
0.1% saponin in PBS, and incubated for 1 h with Abcam anti-LC3B antibody (1:5000), or anti-WIPI2 antibody (1:200), at 37C in a hu-
midity chamber. Cells were rinsed x3with PBS, incubated with a goat anti-rabbit Alexa Fluor 488 secondary antibody (1:1000) diluted
in blocking solution, rinsed, dried and coverslipped with mounting media. 6-10 z stack images were captured for each treatment,
using a Zeiss Axio Observer Z1 inverted microscope, 63x oil immersion lens (1x zoom), connected to a Zeiss LSM710 confocal,
and analyzed with Fiji ImageJ (https://imagej.net/Fiji).
Live-cell confocal microscopy
HEK293 cells were seeded on 35mm coverslip collagen coated dishes (MatTek), cultured to60% confluency, and duplicate plates
were treated for 4 h with V, RB, P1 or RBP1. Z stack images of live cells were acquired with a Zeiss LSM710 confocal with a Zeiss
Observer.Z1 stand and a Zeiss Plan-Apochromat 63x/1.4 objective with a stage incubator maintained at 37C. Mito-Keima fluores-
cence was measured from 600-740nm upon excitation with a 458nm or 561nm laser respectively. Images were analyzed with Fiji
ImageJ (https://imagej.net/Fiji). Experiment was performed a minimum of 2 times.
Cell transfections of plasmids or siRNA
The optimal method for transfection of each cell line was determined experimentally. HEK293 and 293T cells were transfected by the
calcium phosphate method (Chen and Okayama, 1988), using sterile filtered 2X BBS (50 mM BES, 280 mM NaCl,
1.5 mM Na2HPO4) pH 7 and 20X 2.5 M CaCl2 prepared in house. A549 and H9c2 cells were transfected with Lipofectamine
3000, and Hep3b cells with Fugene 6, following manufacturers’ protocols.
Complex I Enzyme Activity
Mitochondrial complex I activity was measured using the Abcam Complex I Enzyme Activity Kit (ab109721) per manufacturer’s
directions. HEK293 cells were seeded at 5.5 3 106 cells per 15 cm dish (n = 16) to reach 70% confluency at 48 h. Cells were
then treated for a minimum of 16 h with V, P1, RB or RBP1 (4 plates each). At harvest time, cells were washed twice with ice cold
PBS, scraped into PBS, and pelleted at 1000 xg. 5%was reserved for further protein analysis, and the remainder was used for isola-
tion of mitochondria, using either the LMF protocol, or Abcam Mitochondria Isolation Kit. Purified mitochondria were suspended in
500 ml Buffer C and lysed for 30 min with detergent (1% lauryl maltoside, final concentration). After centrifugation, mitochondrial pro-
tein was quantified by Bradford andmitochondrial lysates were adjusted to the samemg/ml concentration. Serial dilutions were pre-
pared in incubation solution (Abcam CI Assay Kit). Complex I activity in 200 ml was measured on serial dilutions, each in triplicate, per
manufacture’s protocol, using aMolecular Devices VERSAmaxmicroplate reader at 450nm,with kinetic readings taken every 30 s fore5 Cell Reports 24, 2404–2417.e1–e8, August 28, 2018
30 minutes. Activity is represented as mOD/min. The assay shown is representative of 4 independent experiments, with 2 or
more dilutions.
Mitochondrial DNA content
Mitochondrial DNA content was determined using a quantitative real-time PCR approach, as described (Venegas and Halberg,
2012). In brief, 10 sets of HEK293 cells were treated for 24h with V, RB, P1, and RBP. Total DNA from each plate was isolated using
the QIAGEN DNeasy Blood and Tissue Kit according to manufacturer’s protocol, and quantified using a NanoDrop 2000c (Thermo
Scientific). Four random sets of DNAwere selected for qPCR on an Applied Biosystems 7500 Fast Real-Time PCRSystem, using Fast
SYBR Green Master Mix, and 2 nuclear (n) primer sets against nGAPDH and nACTIN and 2 mitochondrial (mt) primer sets against
mtATPase8 andmtCYTOCHROME b (Morita et al., 2013; Prabhu et al., 2013) (See Key Resources Table). Ct values were determined
for each sample in quadruplicate, andDCt values were determined for each nuclear-mitochondria pair (nGAPDHCt –mtCytbCt) and
(nACTIN Ct – mtATPase8 Ct). Mitochondrial DNA content for each nuclear-mitochondria pair was determined using the formula
2x2(DCt), and averaged. The experiment was repeated using 4 additional sets of DNA.
Liposome preparation
Liposomes were prepared with L-a-phosphatidylserine (PS) (brain, porcine), L-a-phosphatidylcholine (PC) (egg, chicken), and
L-a-phosphatidylethanolamine (PE) (egg, chicken), each initially obtained as a 10 mg/mL stock solution in chloroform (CHCl3). Sus-
pensions of liposomes in HEPES buffered saline (HBS) (20 mMHEPES, 100 mMNaCl, pH 7.4) with total lipid concentrations of 1 mM
were prepared with variable molar ratios of PC, PS, and PE: (a) 8:2:0 PC/PS/PE (mol/mol/mol), (b) 6:2:2 PC/PS/PE (mol/mol/mol), or
(c) 4:2:4 PC/PS/PE (mol/mol/mol). The lipid solutions in CHCl3 were mixed and then dried under Ar(g). HBS was added to the dried
lipid film, incubated (1 h, 22C), and vortexed (3 3 30 s, 22C). The diameter of the resultant liposomes was reduced by sequential
extrusion through a 200-nm and 100-nm polycarbonate membrane filters (Avanti Cat #s 610006 and 610005). The liposomes were
briefly stored on ice prior to use.
Percoll density separation of mitochondria population
Crude mitochondria were isolated and separated by density as previously described (Wieckowski et al., 2009). Starting number of
HEK293 cells was 150-200 3 106 per treatment group, following 4 h treatments as described in text. Briefly, cells were washed
and collected in PBS, disrupted by dounce homogenization in buffer (225 mM mannitol, 75 mM sucrose, 0.1 mM EGTA, 30 mM
Tris-HCL pH 7.4), and crude mitochondria were isolated by multiple centrifugation steps. Mitochondria protein concentrations
were measured by Bradford. 2 mg of mitochondria protein were loaded on a 30%Percoll gradient and centrifuged in an SW-41 rotor
for 35 min, 95,000 g, to separate mitochondria into light and dense fractions. Each fraction was collected, diluted in mitochondria
resuspending buffer (250 mM mannitol, 5 mM HEPES (pH 7.4) and 0.5 mM EGTA), and centrifuged at 6,300 g for 10 min. Pellets
were washed, recentrifuged as before, and resuspended in equal volumes. 10 ug of crude mitochondria and a percentage of recov-
ered fractions were separated by SDS-PAGE, with western blotting for proteins as shown.
Quantitative Real-Time PCR
RNA was isolated from triplicate plates of HEK293 cells transfected with siNS, siPISD-6 and siPISD-7, using the QIAGEN RNeasy kit
per manufacturer’s instructions. For qRT-PCR of PGC1a, NRF1 and TFAM, HEK293 cells were treated for 24 h with V, RB, P1, or
RBP1, prior to RNA isolation. 500 ng of total RNA was used for reverse transcription using Invitrogen Superscript III First Strand Syn-
thesis SuperMix. mRNA gene expression was determined using QuantiNova SYBR Green PCR Kit on the Applied Biosystems 7500
Fast Real-Time PCR System, per manufacturer’s instructions, with normalization to ACTIN. RT2 qPCR primer assays for ACTIN,
PISD, NRF1, PPARGa (PGC1a), and TFAM used in qRT-PCR reactions were purchased from QIAGEN.
Lysosomal pH
Lysosomal pH was measured using LysoSensor Yellow/Blue dextran (Molecular Probes) per recommended protocol. HEK293 cells
were treated for 4.5 h with V, RB, P1, or RBP1. Cells were washed with PBS, trypsinized, centrifuged and resuspended in DMEM.
Cells were counted using Trypan Blue and the Invitrogen Countess Cell Counting chamber system and adjusted to 13 10̂ 6 cells/ml.
1 mL cell aliquots were pelleted by centrifugation, and pellets were resuspended in 50 ml residual DMEM. 50 ml of 2 mg/ml Yellow/
Blue dextran in DMEM was added to each cell pellet for a final concentration of 1 mg/ml dextran, excluding a no-dextran control,
which received DMEM only. Cells were incubated for 2 h at 37C, 5% CO2, washed x3 with Hank’s buffered salt solution (HBSS),
and resuspended in 1 mL HBSS. Samples (100/well) were loaded on a black 96-well plate (8 wells per each) and fluorescence
was monitored using a Clariostar microplate reader with emission wavelengths at 452 nm and 521 nm, and excitation at 335 nm.
The ratio of emissions at 452/521 nm was calculated for each sample, and pH values were calculated from a linear calibration curve.
The calibration curve was generated by incubating cells for 10 min at 37C, prior to dextran loading, with 10 uMmonensin and 10 uM
nigericin in MES buffers (5 mMNaCl, 115 mMKCL, 1.3 mMMgSO4, 25 mMMES), with pHs ranging from 3.5 – 7.0 (Diwu et al., 1999).
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Glycogen measurements
3.5 3 105 HEK293 cells were plated in 6-well dishes and grown to 60%–70% confluence. Cells were treated in triplicate for 6 h
with V, RB, P1 or RBP1. Glycogen measurements were performed in triplicate with 3 separate dilutions, using Abcam’s Glycogen
Assay kit per manufacturer’s instructions. Glycogen levels were determined using a freshly prepared standard curve: slope =
0.6074, r2 = 0.9990.
NAD+/NADH measurements
1.7 3 105 HEK293 cells were plated in 6-well dishes and grown to 50%–60% confluence. Cells were treated in duplicate for 6 h
with V, RB, P1, RBP1, 5 mMNAM, 10 nM FK866, or RBP+NAM and harvested and analyzed for NADH and NAD+ using the BioVision
NAD/NADH Quantitation Colorimetric Kit per manufacturer’s instructions. In brief, cells were washed in cold PBS and scraped into
400 ml cold extraction buffer and disrupted by dounce homogenization (10 strokes), vortexed 10 s, and centrifuged at 4C for 5 min.
Half of the supernatant was heated for 30 min at 60C to decompose NAD, leaving NADH intact (NADH), and quick spun to remove
any precipitates. The remaining half contained total NAD and NADH (NADt). 50 ml of each undiluted sample (total or heated), and each
sample diluted 1:2 and 1:4, was immediately assayed in duplicate in 96-well format. NADCycling Mix (100 ml/well) was added, mixed
and incubated for 5min at RT to convert NAD toNADH, and then 10 ml of NADHdeveloper was added for 1-4 h, and the plate was read
at OD 450 nm after the reactions were stopped with Stop Solution (10 ml). Ratios were calculated as NADH / NADt – NADH.
High performance liquid chromatography (HPLC) analysis of nucleotides
HEK293 cells were plated on 10cm dishes, treated as described in text, and harvested at the times indicated in duplicate. Cells were
rinsed 2 timeswith cold PBS, scraped into 1ml of 80%acetonitrile, and centrifuged at 4C for 5min. Supernatants were heat shocked
at 80C for 3 min, speed vacuumed until dry, and rehydrated with 100-200 ml HPLC water. Following centrifugation, samples were
analyzed by HPLC on a Shimadzu LC-10AT VP systemwith a ZORBAX Extend-C18 column (Agilent). Analyses were performed using
a sample injection volume of 50 ml at room temperature (RT), a flowrate of 1.0 ml/min, and a linear gradient program. Buffer A:
20 mM NaH2PO4 pH 8.5 with NaOH, 10 mM tetrabutyl ammonium hydrogen (TBA); Buffer B: 100 mM NaH2PO4 pH 3.0 with HCl,
10 mM TBA, 30% MeOH; Buffer C: 30% MeOH. The HPLC program was: 0-15 min, 0%B, 0%C; 20 min, 10%B, 0%C; 25min,
15%B, 0%C; 65min, 30%B, 0%C; 85 min, 60%B, 0%C; 95 min, 80%B, 0%C; 95.1 min, 0%B, 100%C; 120 min, 0%B, 100%C;
121 min, 0%B, 0%C; 130 min, stop. UV detection was set at 254 nm wavelength. Peaks were identified by retention times and
compared to the peak spectrum of authentic standards. For ATP analysis in cells supplemented with adenosine, HPLC protocol
was modified as follows: (i) samples were injected at a volume of 60 ul; (ii) Buffer C was not included, and (iii) program
details were 0-20 min, 0%B; 25 min, 15%B; 40 min, 55%B; 70 min, 30%B; 85 min, 60%B; 95 min, 80%B; 110 min, 80%B;
115 min, 0%B; 120 min, stop.
Proximity ligation assay (PLA) for MAMs
The PLA for MAMs followed a previously described protocol (Tubbs and Rieusset, 2016) and the DuoLink InSitu Detection Reagents
Red kit instructions (Sigma). 1.3-1.6 3 105 HEK293T and 1.5-2.2 3 105 NDUFA1KO cells were seeded on 35 mm coverslip collagen
coated dishes (MatTek), cultured to60% confluency, and duplicate plates were treated for 4h with V, RB, P1 or RBP. Control plates
for no antibody or single antibodies were treated with V. Cells were washed with PBS and fixed for 10 min at RT with fresh 4% form-
aldehyde solution in PBS (ThermoScientific Pierce, #28908), whichwas stopped by adding an equal volume of 1Mglycine. Cells were
washed once with PBS, and incubated in 100mMglycine for 15min at RT, permeabilized with 0.1% Triton X-100 in PBS for 15min at
RT, washed once with PBS, and blocked for 30 min at 37C in a humidity chamber with blocking reagent (included in the DuoLink
InSitu PLA Probe kit). Anti-IP3R-1 (rabbit) and anti-VDAC1 (mouse) antibodies were prepared at 1:500 and 1:100 dilutions respec-
tively, and added to cells for overnight incubation, in a humidity chamber at 4C. Plates were washed twice with TBS-Tween
(0.01%) or DuoLink Fluorescent Wash buffer A, then incubated for 1h at 37C in a humidity chamber with DuoLink InSitu PLA Probes,
Anti-Rabbit Plus and Anti-MouseMinus. The ligation and amplification steps, with their incubation times, conditions, and wash steps
were performed per manufacturer’s instructions. After the final washes in 1x and 0.01x DuoLink Fluorescent Wash buffer B, plates
were dried and thenmountedwith round coverslips using aqueousmountingmedia with DAPI (Vector Labs). Aminimum of 10 z stack
images were captured for each cell line and treatment, using a Zeiss Axio Observer Z1 inverted microscope, 63x oil immersion lens
(1x zoom), connected to a Zeiss LSM710 confocal and analyzed with Fiji ImageJ (https://imagej.net/Fiji). Images shown are maximal
projection images. Data are representative of 3 independent experiments in WT and NDUF KO cells, and 2 independent experiments
with glucose starvation.
Targeted phosphatidylethanolamine (PE) and Phosphatidylserine (PS) analysis:
Quantitative analysis of PE andPSwas carried out using aWaters Premier XE triple quadrupolemass spectrometer interfacedwith an
Acquity ultra-high performance liquid chromatography (UPLC) system (Waters, Milford, MA). Mass spectrometer was operated in
electrospray ionization mode with negative ion acquisition. Phospholipids were extracted from cells by the Folch procedure with
initial addition of internal standards, D31-160/181 PE and D31-160/181 PS. Quantification was based on calibration curves con-
structed using PE and PS standards with multiple reactions monitoring function. PE calibration curves include 160 LPE, 181 LPE,e7 Cell Reports 24, 2404–2417.e1–e8, August 28, 2018
160/181 PE, 160,182 PE, 180,182 PE, 180/204 ES. PE and PS species without reference compounds were quantified with
the standard sharing the closest structure. PS calibration curves include 160 LPS, 181 LPS, 180 LPS, 160/181 PS, 160,182 PS,
180,182 PS, 180/204 PS. Final concentration of PE and PSwere normalized to DNA contents in the cell and expressed as ng/mgDNA.
NMR Metabolomics analysis
Sample processing
The hydrophilic cell extracts were dried in a SpeedVac centrifuge for 4-6 h at room temperature, and stored at 20C until data
collection. The dried polar extracts were re-hydrated with 600 mL of NMR buffer containing 100 mM phosphate buffer, pH 7.3,
1 mM TMSP (3-Trimethylsilyl 2,2,3,3-d4 propionate, CAS 24493-21-8), and 1 mg/mL NaN3 (sodium azide CAS 26627-22-8)
prepared in D2O.
Media samples were thawed on ice and centrifuged 4000 x gn for 5 min at 4
C. The 500 mL supernatant of the media samples were
aliquoted onto pre-washed 3 kDa spin filters (NANOSEP 3K, Pall Life Sciences), and centrifuged 10000 x gn for 90 min at 4
C. The
300 mL of media filtrate was mixed with 300 mL of NMR buffer.
NMR data collection
One-dimensional 1H NMR spectra were recorded on all samples using the nuclear overhauser spectroscopy (NOESY) pulse
sequence with presaturation of the water peak on a Bruker Avance II 600 MHz spectrometer. Two-dimensional 13C edited hetero-
nuclear single quantum correlation (HSQC) spectra for representative samples were acquired to assess the metabolites annotation.
All NMR data were processed using Topspin 3.1 software (Bruker Analytik, Rheinstetten, Germany). All FIDs were subjected to an
exponential line-broadening of 0.3 Hz. Upon Fourier transformation, each spectrum was manually phased, baseline corrected,
and referenced to the internal standard TMSP at 0.0 ppm. Metabolites found in cell extract and media were assigned based on
1D 1H and 2D NMR experiments with reference spectra found in databases, such as the Human Metabolome Database and
Chenomx NMR Suite profiling software (Chenomx Inc. version 8.1).
QUANTIFICATION AND STATISTICAL ANALYSIS
Western blot analyses were quantified using the Li-Cor imaging system software. All data, with the exception of NMR and targeted
lipidomics, listed separately below, are presented as mean ± SD. Statistical analyzes utilized GraphPad Prism 7, and statistical sig-
nificance was determined using one-way analysis of variance (ANOVA) with Turkey HSD (Honestly Significant Difference) calculation
to compare multiple treatments.
NMR Metabolomics Data analysis
1H NMR spectra were processed and analyzed with AMIX for PCA analysis and the spectral bucket intensity tables were generated
for further analysis. The spectra from 0.5 to 10.0 ppm, excluding the region of the residual water resonance (4.6 to 5.0 ppm), methanol
(3.36-3.38 ppm), and phenformin (3.49-3.54, 7.29-7.43ppm) were reduced by uniform binning to 1916 buckets 0.005 ppm wide. The
spectra were normalized to constant total spectral area prior to PCA analysis and the binned spectra were mean-centered with no
scaling.
Themetabolites assigned bin-by-bin differences between each group were assessed by univariate approach. Pairwise differences
within each bin were compared using a two-tailed Welch’s t test, the false discovery rate (FDR) was controlled at the 0.05 level using
the Benjamini-Hochberg method (Benjamini and Hochberg, 1995).
DATA AND SOFTWARE AVAILABILITY
The NMR and lipidomics datasets reported in this paper are available at Mendeley Data: https://doi.org/10.17632/ccx58pdy3d.1.Cell Reports 24, 2404–2417.e1–e8, August 28, 2018 e8
